Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obatoclax Mesylate in Systemic Mastocytosis
NCT00918931Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2009
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of obatoclax in systemic mastocytosis (SM) and mast cell leukemia (MCL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate at 3 months. Started Jun 2009; status: terminated.
02
Drugs
obatoclax
03
Conditions
systemic mastocytosis (SM)mast cell leukemia (MCL)
Beyond the preview
Go deeper on NCT00918931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00918931.